論文・出版
Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey.
Kosuke Kawaguchi, Hiroshi Ishiguro, Satoshi Morita, Seigo Nakamura, Shinji Ohno, Norikazu Masuda, Hiroji Iwata, Kenjiro Aogi, Katsumasa Kuroi, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
Breast Cancer Research and Treatment. 2011; 130(2): 627-634.
https://doi.org/10.1007/s10549-011-1641-9
Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
Masahide Kondo, Shu-Ling Hoshi, Takeharu,Yamanaka, Hiroshi Ishiguro, Masakazu Toi
Breast Cancer Research and Treatment. 2011 Jun; 127(3): 739-49.
https://doi.org/10.1007/s10549-010-1243-y
Japan Breast Cancer Research Group (JBCRG)
黒井克昌、柏 喜代美、戸井雅和、中村清吾、岩田広治、大野真司、増田慎三、青儀健二郎、佐藤信昭、笹野公伸
腫瘍内科. 2010; 6(4): 360-368.
Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population
Masakazu Toi, Hiroji Iwata, Takeharu Yamanaka, Norikazu Masuda, Shinji Ohno, Seigo Nakamura, Takahiro Nakayama, Masahiro Kashiwaba, Shunji Kamigaki, Katsumasa Kuroi; and the Japan Breast Cancer Research Group-Translational Research
Cancer.2010 Jul; 116(13): 3112-3118
https://doi.org/10.1002/cncr.25206
JBCRG-07
増田慎三
Cancer Board 乳癌. 2010; 3(1): 92.
JBCRG-M02
黒井克昌
Cancer Board 乳癌, 2010; 3(1): 91.
「術前化学療法; 治療効果の評価」みんなに役立つ乳癌の基礎と臨床(戸井雅和 編集)
黒井克昌
みんなに役立つ乳癌の基礎と臨床(戸井雅和 編). 医薬ジャーナル社, 2009; 654-662.
術前薬物療法の新展開―JBCRG studyのあゆみ
山城大泰 戸井雅和
医学のあゆみ. 2009; 230(1): 57-61.
SUPREMO(BIG2-04)試験.
黒井克昌
Cancer Board 乳癌. 2009; 2(1): 68.
ALTTO試験.
黒井克昌
Cancer Board 乳癌. 2008; 1(1): 58.